Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following ...

根据最近的一份文件显示，Akero Therapeutics, Inc. (NASDAQ: AKRO )的首席开发官Yale Catriona最近出售了大量公司股票。1月27日，Catriona总共出售了48,074股Akero Therapeutics普通股。这些股票以55.152美元至57.007美元的价格出售，总计约273万美元。

根据最近的SEC文件显示，Akero Therapeutics Inc.（纳斯达克股票代码：AKRO）商业战略高级副总裁Patrick Lamy执行了一系列涉及公司普通股的交易。1月27日，Lamy以平均57.03美元的价格出售了5,000股，总计285,150美元。这次出售是之前制定的Rule 10b5-1交易计划的一部分。这笔交易发生之际，这家市值38亿美元的生物科技公司股票显示出显著的动能， ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...

Akero Therapeutics, Inc. has successfully completed its underwritten public offering, selling 6,427,170 shares of common stock at $48.00 per share, including an over-allotment option for an ...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...

Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.

In subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.